RADIATION THERAPY TECHNIQUES AND COMBINATION TREATMENTS FOR SARCOMA
Professor Angela Hong, Director and
co-Chair of Scientific Advisory Committee,
Australia and New Zealand Sarcoma Association  (ANZSA) @anzsarcoma 

RESEARCHER PROFILE
Filmed Sydney, Australia | January 2025
 
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney @Sydney_Uni . She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse @COBLH  for the past 15 years.

She is also the Director and co-chair of the Scientific Advisory Committee for the Australia and New Zealand Sarcoma Association (ANZSA), a non-profit organisation aimed at enhancing treatment outcomes for sarcoma patients across Australia and New Zealand.

As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.

After earning her medical degree from the University of Sydney, Angela undertook an 18-month fellowship in the United States to gain additional experience before returning to Sydney to start her formal training in radiation oncology. She later completed her PhD, concentrating on radiosensitivity in skin cancer sarcoma.

Professor Hong believes in a multidisciplinary approach to managing sarcoma, given its rarity and the complexities involved in diagnosis and treatment. She is actively involved in clinical research and recently contributed to an international trial led by Sarcoma Alliance for Research through Collaboration (SARC) @SARCtrials  in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The trial examined the advantages of including immunotherapy in the treatment regimen for high-risk soft tissue sarcoma, resulting in a notable improvement in two-year disease-free survival rates.

SEE OTHER RESEARCHER PROFILES
Bench Side Story @BenchSideStory